VaccineHumansAnthrax VaccinesDouble-Blind MethodMaleAdult
Immunogenicity and safety evaluation of a recombinant protective antigen anthrax vaccine (GC1109): A phase II, dose-confirmed, randomized, double-blind, placebo-controlled study.
Chang Kyung Kang, Young Jin Im, Dah Yoon Kim, Pyoeng Gyun Choe, Yae Jee Baek, Eunjung Lee, Won Suk Choi, Seong-Heon Wie, Yu Bin Seo, Jacob Lee, Nam Joong Kim, Myoung-Don Oh
Published: 202510.1016/j.vaccine.2025.127819
Abstract
BACKGROUND: GC1109, a novel recombinant protective antigen (PA) anthrax vaccine, has demonstrated promising immunogenicity in previous dose-finding trials. This study evaluated the immunogenicity and safety of four intramuscular doses of GC1109 in he…
Preview only. Read the full abstract at the source